DG
MAZE

David Goel’s Maze Therapeutics MAZE Stock Holding History

David Goel’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-480,000
Closed -$19.9M – 2
2025
Q4 		$19.9M Sell
480,000
-1,173,684
-71% -$40.3M 34.52% 2
2025
Q3 		$42.9M Sell
1,653,684
-832,500
-33% -$14.1M 40.17% 1
2025
Q2 		$30.5M Hold
2,486,184
– – 13.69% 3
2025
Q1 		$27.4M Buy
+2,486,184
New +$29.9M 7.88% 3

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

David Goel's MAZE Position: Q1 2026 in Review

David Goel sold out of Maze Therapeutics (MAZE) in Q1 2026, closing a stake of 480,000 shares — an estimated $19.9M sold.

David Goel first reported a position in MAZE in Q1 2025 and held it in 4 quarters. The position peaked at $42.9M in Q3 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • David Goel reported no remaining Maze Therapeutics position as of Q1 2026 after selling out during the quarter.
  • David Goel sold 480,000 Maze Therapeutics shares in Q1 2026, an estimated $19.9M.
  • David Goel first reported a position in Maze Therapeutics in Q1 2025 and held it in 4 quarters.
  • David Goel's Maze Therapeutics position peaked at $42.9M in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Matrix Capital Management Company's 13F filing for Q1 2026, filed 14 May 2026.